Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.53M Sell
1,147,048
-153,212
-12% -$925K ﹤0.01% 2043
2026
Q1
$8.01M Buy
1,300,260
+501,901
+63% +$4.17M 0.01% 1578
2025
Q4
$8.32M Buy
798,359
+135,942
+21% +$1.36M 0.01% 1248
2025
Q3
$5.96M Buy
662,417
+221,961
+50% +$1.95M 0.01% 1318
2025
Q2
$5.73M Buy
440,456
+321,566
+270% +$4.83M 0.01% 1146
2025
Q1
$3M Sell
118,890
-8,462
-7% -$251K 0.01% 1460
2024
Q4
$4.38M Sell
127,352
-154,871
-55% -$6.98M 0.01% 1184
2024
Q3
$14M Sell
282,223
-59,693
-17% -$3.06M 0.03% 623
2024
Q2
$20.6M Sell
341,916
-41,215
-11% -$2.36M 0.05% 450
2024
Q1
$19.8M Buy
383,131
+102,819
+37% +$5.05M 0.05% 443
2023
Q4
$11.3M Sell
280,312
-30,554
-10% -$896K 0.03% 618
2023
Q3
$8.67M Buy
310,866
+34,744
+13% +$1.04M 0.02% 658
2023
Q2
$7.95M Buy
276,122
+256,673
+1,320% +$5.71M 0.02% 733
2023
Q1
$324K Buy
+19,449
New +$275K ﹤0.01% 2388

Other funds holding RXST

John Overdeck's RXST Position: Q2 2026 in Review

John Overdeck reduced its RxSight (RXST) stake by 12% in Q2 2026, selling an estimated $925K and leaving 1,147,048 shares worth $5.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

John Overdeck first reported a position in RXST in Q1 2023 and has held it in 14 quarters since. The position peaked at $20.6M in Q2 2024. 150 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • John Overdeck held 1,147,048 shares of RxSight worth $5.53M as of Q2 2026.
  • John Overdeck sold 153,212 RxSight shares in Q2 2026, an estimated $925K.
  • RxSight made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2043 holding.
  • John Overdeck first reported a position in RxSight in Q1 2023 and has held it in 14 quarters since.
  • John Overdeck's RxSight position peaked at $20.6M in Q2 2024.
  • 150 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.